June 23, 2021, 6:58 PM; Updated: June 23, 2021, 8:35 PM
Mylan NV and its former CEO—the daughter of Sen. Joe Manchin (D-W. Va.)—lost their bid Wednesday to end price-gouging litigation over its lifesaving EpiPen, but the drugmaker got a federal judge in Kansas to dismiss a host of class action claims.
Judge Daniel D. Crabtree pared back some of the lawsuit’s allegations, including its racketeering counts, but left the case on track for a September trial of antitrust claims in the U.S. District Court for the District of Kansas on behalf of “end payers” like consumers, insurers, and pension funds.
There’s enough evidence for a jury to conclude Mylan unlawfully ...
